Tech Company Financing Transactions
Generation Bio Funding Round
T. Rowe Price, Atlas Venture and Casdin Capital participated in a $110 million Series C funding round for Generation Bio. The round was announced on 1/13/2020.
Transaction Overview
Company Name
Announced On
1/13/2020
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to advance its two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-enabling studies and clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
301 Binney St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Generation Bio is creating a breakthrough class of genetic medicines that deliver durable, high levels of gene expression and can be re-dosed to titrate and sustain effect.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoff Mcdonough
Chief Financial Officer
Thomas Graney
Chief Operating Officer
Mark Angelino
Chief Scientific Officer
Matthew Stanton
VP - Bus. Development
Douglas Kerr
VP - Bus. Development
William McCarthy
VP - General Counsel
Jennifer Elliott
VP - Human Resources
Sara Besten
VP - Human Resources
Antoinette Paone
Browse more venture capital transactions:
Prev: 1/13/2020: Tyton BioSciences venture capital transaction
Next: 1/13/2020: Inflammatix venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs